Almanack Investment Partners’s GSK GSK Stock Holding History

Almanack Investment Partners’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-5,539	Closed	-$239K	–	188
2025 Q3	$239K	Buy	+5,539	New	+$216K	0.04%	174
2022 Q4	–	Sell	-9,280	Closed	-$273K	–	586
2022 Q3	$273K	Buy	9,280 +3,800	+69%	+$144K	0.05%	116
2022 Q2	$301K	Hold	5,480	–	–	0.03%	317
2022 Q1	$303K	Hold	5,480	–	–	0.03%	361
2021 Q4	$306K	Buy	+5,480	New	+$285K	0.02%	366
2020 Q4	–	Sell	-10,807	Closed	-$267K	–	421
2020 Q3	$267K	Buy	+10,807	New	+$541K	0.03%	317

Other funds holding GSK

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Holocene Advisors New York $44.4B AUM 57.89% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Almanack Investment Partners's GSK Position: Q4 2025 in Review

Almanack Investment Partners sold out of GSK (GSK) in Q4 2025, closing a stake of 5,539 shares — an estimated $239K sold.

Almanack Investment Partners first reported a position in GSK in Q3 2020 and held it in 6 quarters. The position peaked at $306K in Q4 2021. 998 funds tracked by Wall St. Rank hold GSK as of Q4 2025.

Almanack Investment Partners reported no remaining GSK position as of Q4 2025 after selling out during the quarter.
Almanack Investment Partners sold 5,539 GSK shares in Q4 2025, an estimated $239K.
Almanack Investment Partners first reported a position in GSK in Q3 2020 and held it in 6 quarters.
Almanack Investment Partners's GSK position peaked at $306K in Q4 2021.
998 funds tracked by Wall St. Rank held GSK as of Q4 2025.

Based on Almanack Investment Partners's 13F filing for Q4 2025, filed 29 Jan 2026.